DNA Vaccine Market Statistics 2030
The global DNA vaccine market size was valued at $422.77 Million in 2020 and is projected to reach $774.43 Million by 2030 registering a CAGR of 6.3% from 2021 to 2030. DNA vaccination is a technique for protecting an individual against disease by injecting it with genetically engineered DNA so cells directly produce an antigen, resulting in a protective immunological response. It consists of delivering genes or fragments of it, encoding immunogenic antigens to the host's cells by using DNA plasmids as a vector. This approach induces both humoral and cell-mediated immune responses efficiently.
Increase in number of cases of cancer and infectious diseases in human and animals, as well as growth in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature are some factors that drive the DNA vaccine market. In addition, rise in number of antibiotics resistant pathogens, further boost the growth of the DNA vaccines market. Moreover, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies creates an opportunity for the manufacturers to tap and capitalize on the market. However, lack of immunogenicity associated with DNA vaccines, may hamper the growth of the market. In addition, limited knowledge of the effects of DNA vaccines on humans, also hinder the growth of the market.
What is the Impact of COVID-19 Pandemic on the DNA Vaccines Market?
The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. Moreover, there has also been a negative effect on various services, including DNA vaccine market. The existing scenario evidently states that COVID-19 is expected to continue to limit several aspects of the healthcare sector in the future, until an effective treatment can be made accessible to population on a larger scale.
Impact of the pandemic on animal health industry is possibly expected to be deeper and long lasting. Nationwide lockdowns, government regulations, and continuous increase in infection rate across numerous countries has created a widespread financial impact on veterinary care centers. Large number of hospitals and clinics has witnessed a drop in number of veterinary patient visits amid COVID-19 ultimately reducing client contact.
Dna Vaccines Market Segmentation
The global DNA vaccine market is segmented on the basis of product type, type, end user, and region to provide a detailed assessment of the market. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on end user, it is categorized into veterinary clinics, veterinary hospitals. Region wise, the market is analyzed only across North America as DNA vaccine products are not approved in others region.
Segment Review
Based on product type, the market is segmented into Oncept, West Nile-Innovator, and Apex-IHN. The Oncept held the largest market share in 2020 and is expected to remain dominant throughout the forecast period owing to growth in prevalence of canine melanoma cancer in animals, especially in dogs, which increases demand for Oncept vaccine.
Based on type, it is segmented into therapeutic vaccine, and prophylactic vaccines. The prophylactic vaccines segment dominated the global DNA vaccine market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to, availability of prophylactic vaccines for the treatment of animal diseases such as West Nile virus, and Hematopoietic Necrosis virus.
Based on end user, it is classified into veterinary clinics and veterinary hospitals. The veterinary hospitals held the largest market share in 2020 and is expected to remain dominant throughout the forecast period owing to rise in incidences of animal diseases, increase in hospital admissions of animals for vaccine dose, and availability of trained veterinarian in the hospitals.
By Product Type
Oncept segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Snapshot of the North America DNA Vaccine Market
The DNA vaccine product such as Oncept, West Nile Innovator vaccines, and Apex-IHN vaccines, for the treatment of animal diseases only approved in the U.S and Canada in the North America region. U.S. accounted for a major share in the DNA vaccine market in 2020, and is expected to maintain its dominance during the forecast period, owing to factors such as DNA vaccine product approval in these country, presence of major key players, and presence of well-established veterinary organizational structures, higher buying power, and higher animal healthcare expenditure levels.
By Type
Prophylactic Vaccines Segment is projected as one of the most lucrative segment.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global DNA vaccine market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the DNA vaccine market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing DNA vaccine market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of DNA vaccines used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the DNA vaccine market.
DNA Vaccine Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Type |
|
 By END USER |
|
 By Region |
|
 Key Market Players | GEOVAX LABS, INC., GENEONE LIFE SCIENCE, TAKARA HOLDINGS (TAKARA BIO), ELI-LILLY (NOVARTIS ANIMAL HEALTH), GENEXINE, INC, INOVIO PHARMACEUTICALS (VGX ANIMAL HEALTH), ZOETIS INC. (FORT DODGE ANIMAL HEALTH), ZYDUS CADILA, BOEHRINGER INGELHEIM GmbH (MERIAL), VIATRIS INC. (ROTTAPHARM BIOTECH) |
Analyst Review
DNA vaccine is a circular double stranded DNA molecule, referred to as a plasmid, containing genes encoding one or more proteins of a pathogen.
Rise in prevalence of cancer and infectious diseases in human and animals, increase in demand for DNA vaccines, and increase in number of antibiotics resistant pathogens, are some factors which boost the growth of the market. Furthermore, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are expected to create a lucrative opportunity for market growth. However, lack of immunogenicity associated with DNA vaccines, and limited knowledge of the effects of DNA vaccines on humans are some factors that are expected to hinder growth of the market.
The Oncept segment is expected to remain dominant during the forecast period, owing to increase in prevalence of canine melanoma cancer in animals, especially in dogs, which increases the demand for Oncept vaccine.
The total market value of DNA vaccine Market is $422.77 million in 2020.
The forcast period for DNA vaccine Market is 2021 to 2030
The market value of DNA vaccine Market in 2021 is $447.71 million.
The base year is 2020 in DNA vaccine Market
Top companies such asThe Eli-Lilly, Boehringer Ingelheim GmbH, Inovio Pharmaceuticals, Viatris, Zoetis Inc. and Zydus Cadila held a high market position in 2020.
Oncept segment is the most influencing segment owing to increase in prevalence of canine melanoma cancer in animals, especially in dogs, also increases demand for Oncept vaccine.
Rise in prevalence of cancer and infectious diseases in human and animals, increase in demand for DNA vaccines, and increase in number of antibiotics resistant pathogens, are some factors which boost the growth of the market. Furthermore, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are expected to create a lucrative opportunity for market growth
U.S. was the largest revenue contributor in North America in 2020, and is a mature market owing to factors such as DNA vaccine product approval in the country, presence of major key players, presence of well-established healthcare infrastructure, higher buying power, and higher healthcare expenditure levels
A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.
DNA vaccines work by injecting genetically engineered plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, so the cells directly produce the antigen, thus causing a protective immunological response.
Loading Table Of Content...
